Chongqing Genrix Biopharmaceutical Co (SHSE:688443) Total Long-Term Liabilities : ¥915.90 Mil (As of Mar. 2025)

View and export this data going back to 2023. Start your Free Trial

What is Chongqing Genrix Biopharmaceutical Co Total Long-Term Liabilities?

Total Long-Term Liabilities includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities. Chongqing Genrix Biopharmaceutical Co's Total Long-Term Liabilities for the quarter that ended in Mar. 2025 was ¥915.90 Mil.

Chongqing Genrix Biopharmaceutical Co Total Long-Term Liabilities Historical Data

The historical data trend for Chongqing Genrix Biopharmaceutical Co's Total Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chongqing Genrix Biopharmaceutical Co Total Long-Term Liabilities Chart

Chongqing Genrix Biopharmaceutical Co Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Long-Term Liabilities

Get a 7-Day Free Trial

393.32

604.83

806.66

673.49

845.39

Chongqing Genrix Biopharmaceutical Co Quarterly Data
	Dec19	Dec20	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Long-Term Liabilities	Get a 7-Day Free Trial												672.55	673.01	782.86	845.39	915.90

Chongqing Genrix Biopharmaceutical Co Total Long-Term Liabilities Calculation

Total Long-Term Liabilities represents the obiligation that incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle, excluding minority interest. It includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities.

Chongqing Genrix Biopharmaceutical Co Total Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Chongqing Genrix Biopharmaceutical Co's Total Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Chongqing Genrix Biopharmaceutical Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chongqing Genrix Biopharmaceutical Co Ltd (SHSE:688443) » Definitions » Total Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 699, Maliu Avenue, Area A, Building 2, International Bio City, Banan, Chongqing, CHN, 401338

Website

http://www.genrixbio.com

Chongqing Genrix Biopharmaceutical Co Ltd is engaged in the research & development, production and sales of antibody drugs. The company has a total of more than ten products under research covering three major therapeutic areas. The progress of core products is leading, and some product pipelines are as follows; autoimmune disease, infectious disease, and tumor. Its product Xeligekimab injection (Xeligekimab) is a recombinant fully human anti-IL-17A monoclonal antibody independently developed by the company, which has been accepted by the National Medical Products Administration (NMPA) for new drug marketing applications.

Executives

Jiang Ren Sheng

Director

Chongqing Genrix Biopharmaceutical Co Headlines

No Headlines